Biotechs generally need access to a lot of capital in order to bring their therapeutics to market. The traditional IPO route was the classic way a Biotech was able to access the public market. Today there is another option - a de-SPAC merger with a SPAC. There are many reasons to choose one approach over the other - valuation, cost of capital, dilution, etc. but now Biotechs looking to go public have another way to do it. Our client DermTech is a great example of a very successful healthcare SPAC.
| less than a minute read
SPACs are an Increasingly Attractive Option for Biotech Companies
Biotechnology startups can increasingly go public on their own terms as investors and blank-check companies clamor for access to the hottest new drugmakers.
![featured image](https://images.passle.net/fit-in/860x860/Passle/5f7c32f353548911309c42df/SearchServiceImages/2021-02-25-14-07-51-988-6037af375354890b7867bc99.jpg)